Pharmaceutical preparations for the treatment of metabolic diseases and orphan diseases, namely, overactivation of insulin receptor by insulin or insulin-like substances, including congenital hyperinsulinism, tumor hyperinsulinism caused by insulinomas and non-islet cell tumors (IGF-2 mediated), transient hypoglycemia (e.g., perinatal stress or related causes), post-bariatric hyperinsulinism (PBHI), post-gastrectomy hyperinsulinism, nesidioblastosis, activating insulin receptor autoantibodies...